Suppr超能文献

淋巴结评估与早期胆囊癌手术后生存率的提高相关。

Lymph node evaluation is associated with improved survival after surgery for early stage gallbladder cancer.

作者信息

Jensen Eric H, Abraham Anasooya, Jarosek Stephanie, Habermann Elizabeth B, Al-Refaie Waddah B, Vickers Selwyn A, Virnig Beth A, Tuttle Todd M

机构信息

Division of Surgical Oncology, University of Minnesota Medical Center, Minneapolis, MN 55455, USA.

出版信息

Surgery. 2009 Oct;146(4):706-11; discussion 711-3. doi: 10.1016/j.surg.2009.06.056.

Abstract

BACKGROUND

Guidelines for the current National Comprehensive Cancer Network recommend radical cholecystectomy, including hepatic resection and portal lymph node (LN) dissection, for patients with early stage gallbladder (GB) cancer. We sought to determine the survival benefit conferred by adequate LN evaluation.

METHODS

We used the surveillance, epidemiology and end results (SEER) neoplasm registry to identify patients who had an operation for GB cancer between 1988 and 2004. Patients were classified by stage of disease, operative procedure performed (cholecystectomy alone or radical resection), number of LNs evaluated (0, 1, >1), and receipt of radiation (RT). We included patients with T1B, T2, and T3 neoplasms who were LN positive or negative. Patients with T4 neoplasms and those with metastatic disease were excluded. Multivariate analysis included adjustment for age, race, sex, neoplasm grade, stage, operation performed, receipt of RT, and neoplasm registry.

RESULTS

We identified 4,614 patients who underwent operative treatment for stage 1-2B GB (including T1B-T3 and LN positive or negative) cancer between 1988 and 2004. Of 4,614 patients, 9.6% (442) had radical resection, whereas 90.4% (4,172) had cholecystectomy alone. Among patients undergoing radical resection, 56% had LNs evaluated as compared with 28% of patients after cholecystectomy. For patients with T1B and T2 neoplasms who underwent radical resection, pathologic evaluation of at least 1 LN was associated with a significant improvement in median overall survival (OS) compared with those who had no LN evaluated (123 months vs 22 months; P < .0001). Radical resection with no LN evaluation provided similar OS compared with cholecystectomy alone (22 months vs 23 months; P = NS). For patients with T3 neoplasms, radical resection, including pathologic evaluation of at least 1 LN, was also associated with improved OS compared with radical resection with no LN evaluation (12 months vs 7 months; P = .0014). Again, individuals who had radical resection without LN evaluation had similar OS compared with those who had cholecystectomy alone (7 months vs 6 months; P = NS). Individuals who had radical resection with LN evaluation were more likely to receive RT than those who had radical resection without LN evaluation (33.1% vs 19.1%; P = .002). In multivariate analysis (including adjustment for RT), however, LN evaluation was still associated with a decrease in mortality compared with no LN evaluated (HR = 0.611; 95% CI = 0.484, 0.770). The pathologic evaluation of additional LN (>1) did not provide any additional benefit compared with the evaluation of a single node (HR = 0.795; 95% CI = 0.571, 1.107). Radical resection alone (without LN evaluation) did not provide any benefit over cholecystectomy alone (HR = 1.098; 95% CI = 0.971, 1.241).

CONCLUSION

LN evaluation is a critical component of radical resection for GB cancer. In the absence of LN evaluation, radical resection provides no benefit over cholecystectomy alone.

摘要

背景

当前美国国立综合癌症网络指南推荐对早期胆囊癌患者行根治性胆囊切除术,包括肝切除和门静脉淋巴结清扫。我们试图确定充分的淋巴结评估所带来的生存获益。

方法

我们利用监测、流行病学和最终结果(SEER)肿瘤登记系统,识别1988年至2004年间接受胆囊癌手术的患者。根据疾病分期、所施行的手术方式(单纯胆囊切除术或根治性切除术)、评估的淋巴结数量(0个、1个、>1个)以及是否接受放疗(RT)对患者进行分类。我们纳入了肿瘤为T1B、T2和T3且淋巴结阳性或阴性的患者。排除肿瘤为T4以及有转移性疾病的患者。多因素分析包括对年龄、种族、性别、肿瘤分级、分期、所施行的手术、是否接受放疗以及肿瘤登记系统进行校正。

结果

我们识别出1988年至2004年间4614例接受1-2B期胆囊癌(包括T1B-T3且淋巴结阳性或阴性)手术治疗的患者。在4614例患者中,9.6%(442例)接受了根治性切除术,而90.4%(4172例)仅接受了胆囊切除术。在接受根治性切除术的患者中,56%的患者进行了淋巴结评估,而在接受胆囊切除术后的患者中这一比例为28%。对于接受根治性切除术的T1B和T2肿瘤患者,与未进行淋巴结评估的患者相比,至少评估1个淋巴结的病理评估与中位总生存期(OS)的显著改善相关(123个月对22个月;P <.0001)。未进行淋巴结评估的根治性切除术与单纯胆囊切除术的OS相似(22个月对23个月;P =无统计学意义)。对于T3肿瘤患者,与未进行淋巴结评估的根治性切除术相比,包括至少评估1个淋巴结的病理评估的根治性切除术也与OS改善相关(12个月对7个月;P =.0014)。同样,未进行淋巴结评估而接受根治性切除术的患者与单纯接受胆囊切除术的患者OS相似(7个月对6个月;P =无统计学意义)。与未进行淋巴结评估而接受根治性切除术的患者相比,进行淋巴结评估而接受根治性切除术的患者更有可能接受放疗(33.1%对19.1%;P =.002)。然而,在多因素分析(包括对放疗进行校正)中,与未进行淋巴结评估相比,淋巴结评估仍与死亡率降低相关(风险比[HR]=0.611;95%置信区间[CI]=0.484,0.770)。与评估单个淋巴结相比,额外淋巴结(>1个)的病理评估未提供任何额外益处(HR =0.795;95%CI =0.571,1.107)。单纯根治性切除术(未进行淋巴结评估)与单纯胆囊切除术相比未提供任何益处(HR =1.098;95%CI =0.971,1.241)。

结论

淋巴结评估是胆囊癌根治性切除术的关键组成部分。在未进行淋巴结评估的情况下,根治性切除术与单纯胆囊切除术相比无益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验